U.S. markets closed

Rigel Pharmaceuticals, Inc. (RIGL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.2200+0.0200 (+0.48%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close4.2000
Open4.0700
Bid4.1300 x 1800
Ask4.2900 x 1300
Day's Range4.0650 - 4.2700
52 Week Range1.7400 - 5.5000
Volume5,681,192
Avg. Volume2,687,471
Market Cap718.092M
Beta (5Y Monthly)1.51
PE Ratio (TTM)N/A
EPS (TTM)-0.0760
Earnings DateAug 02, 2021 - Aug 06, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est8.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Rigel to Present at the Jefferies Virtual Healthcare Conference
    PR Newswire

    Rigel to Present at the Jefferies Virtual Healthcare Conference

    Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 1:00 p.m. Eastern Time.

  • Rigel Appoints Alison L. Hannah, M.D. to Board of Directors
    PR Newswire

    Rigel Appoints Alison L. Hannah, M.D. to Board of Directors

    Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Alison L. Hannah, M.D. to its Board of Directors. Dr. Hannah brings over three decades of pharmaceutical industry experience to Rigel, including a deep knowledge of clinical development strategy in hematology and oncology with a focus on molecularly targeted therapies.

  • Rigel Pharmaceuticals (RIGL) Tops Q1 Earnings and Revenue Estimates
    Zacks

    Rigel Pharmaceuticals (RIGL) Tops Q1 Earnings and Revenue Estimates

    Rigel (RIGL) delivered earnings and revenue surprises of 2100.00% and 102.24%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?